Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Stemming the spread of cancer

By R&D Editors | September 20, 2012

(Okayama, Japan, 20 September 2012) – Okayama University
researchers demonstrate that cancer stem cells can be produced from
normal stem cells for new therapies to combat cancer

Angiogenesis
Angiogenesis

PRESS RELEASE

Source: Okayama University, Planning and Public Information
Division

For immediate release: 20 September 2012

Okayama University researchers demonstrate that cancer stem cells
can be produced from normal stem cells for new therapies to combat
cancer

(Okayama, Japan, 20 September 2012) Okayama University’s
Masaharu Seno and colleagues have demonstrated in vitro the
development of cancer stem cells (CSCs) from a type of normal stem
cell exposed to their hypothetical microenvironment of a tumor. The
findings are also described in the inaugural September issue of
Okayama University e-Bulletin:
http://www.okayama-u.ac.jp/user/kouhou/ebulletin/index.html

Cancer stem cells (CSCs) have been proposed as an explanation for
the spread of cancer. These cells are tumorigenic and have the
capacity of both self-renewal and differentiation into a range of
various cell types. In this concept, malignant tumors provide
heterogeneous aspects derived from CSCs as well as normal stem
cells provide tissue specific phenotype in response to their
microenvironment.

Researchers have now demonstrated in vitro the development of CSCs
from a type of normal stem cell exposed to their hypothetical
microenvironment of a tumor. The results are the work of a group of
scientists led by Masaharu Seno, a professor of Okayama University,
with his collaborators in China and the US.

The researchers cultured mouse induced pluripotent stem (miPS)
cells in a conditioned medium obtained from a number of mouse
cancer cell lines. Finally, a population of stem cells was kept
undifferentiated and proliferating while other stem cells
differentiated into specialized cells, which were incapable of
proliferation any more.

Since the survived miPS cells treated with the conditioned medium
were found malignantly tumorigenic in vivo, they concluded that the
cells could be defined as CSCs . “The model of CSCs and the
procedure of their establishment will help study the genetic
alterations and the secreted factors in the tumor microenvironment
which convert miPS cells to CSCs,” explain the authors. The
work should help breakthrough towards the development of new
therapies to combat cancer.

Further information:

Okayama University

1-1-1 Tsushima-naka , Kita-ku ,

Okayama 700-8530, Japan

Planning and Public Information Division

E-mail: [email protected]

Website: http://www.okayama-u.ac.jp/index_e.html

About Okayama University

Okayama University is one of the largest comprehensive universities
in Japan with roots going back to the Medical Training Place
sponsored by the Lord of Okayama and established in 1870. Now with
1,300 faculty and 14,000 students, the University offers courses in
specialties ranging from medicine and pharmacy to humanities and
physical sciences. Okayama University is located in the heart of
Japan approximately 3 hours west of Tokyo by Shinkansen.

Website: http://www.okayama-u.ac.jp/index_e.html

Spheroid GFP
Spheroid GFP

Immunostain
Immunostain

Journal information

Authors: Ling Chen1,2,3, Tomonari Kasai1, Yueguang Li4, Yuh
Sugii1, Guoliang Jin1, Masashi Okada1, Arun Vaidyanath1, Akifumi
Mizutani1, Ayano Satoh5, Takayuki Kudoh1, Mary J. C. Hendrix6,
David S. Salomon7, Li Fu8, Masaharu Seno1

ûTitle of original paper: A model of cancer stem cells
derived from mouse induced pluripotent stem cells

ûJournal, volume, pages and year: PLoS One 7, e33544
(2012).

ûDigital Object Identifier (DOI):
10.1371/journal.pone.0033544

ûAffiliations:

1 Department of Medical and Bioengineering Science, Graduate School
of Natural Science and Technology, Okayama University, Okayama,
Japan.

2 Japan Society for the Promotion of Science, Tokyo, Japan.

3 Department of Pathology, Tianjin Central Hospital of Gynecology
Obstetrics, Tianjin, People’s Republic of China.

4 Department of General Surgery, Tianjin 4th Centre Hospital,
Tianjin, People’s Republic of China.

5 Multidisciplinary Division, Okayama University, Okayama,
Japan.

6 Children’s Memorial Research Center, Feinberg School of
Medicine, Northwestern University, Chicago, Illinois, United States
of America.

7 Laboratory of Mammary Biology and Tumorigenesis, Center for
Cancer Research, National Cancer Institute, National Institutes of
Health, Bethesda, Maryland, United States of America.

8 State Key Laboratory of Breast Cancer Research, Department of
Breast Cancer Pathology and Research Laboratory, Cancer Hospital of
Tianjin Medical University, Tianjin, People’s Republic of
China

SOURCE

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE